Methotrexate for multiple sclerosis

Cochrane Database of Systematic Reviews

Volumn 2010, Issue 10, 2004, Pages

  Gray, Orla ^a   McDonnell, Gavin V ^a   Forbes, Raeburn B ^b  

^a ROYAL VICTORIA HOSPITAL   (United Kingdom)

^b CRAIGAVON AREA HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; METHOTREXATE;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HUMAN; MULTIPLE SCLEROSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW;

HUMANS; IMMUNOSUPPRESSIVE AGENTS; METHOTREXATE; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; RANDOMIZED CONTROLLED TRIALS;

EID: 3843076524     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD003208.pub2     Document Type: Review

References (10)

1. Goodkin DE, Rudick RA, VanderBrug Medendorp S, Daughtry MM, Schwetz KM, Fischer J, Van Dyke C. Low dose (7.5mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Annals of Neurology 1995;37:30-40.
2. Currier RD, Haerer AF, Meydrech EF. Low dose oral methotrexate treatment of multiple sclerosis: a pilot study. Journal of Neurology, Neurosurgery and Psychiatry 1993;56:1217-1218.
3. Calabresi P, Chabner B. Antineoplastic agents. In: Gilman A, Rall T, Nies A, Taylor P editor(s). The Pharmacological Basis of Therapeutics. 8th Edition. New York: Pergamon, 1990:1209-63.
4. Colsky J, Greenspan E, Warren T. Hepatic fibrosis in children with acute leukemia after therapy with folate antagonists. Archives of Pathology 1955;59:198-206.
5. Cronstein B, Naime D, Ostad E. The anti-inflammatory effects of methotrexate. Journal of Clinical Investigation 1993;92:2675-82.
6. Hawkins SA, McDonnell GV. Benign multiple sclerosis? Clinical course, long term follow up, and assessment of prognostic factors. Journal of Neurology Neurosurgery and Psychiatry 1999;67:148-52.
7. Hunter S, Weinshenker B, Carter J, Noseworthy J. Rational clinical immunotherapy for multiple sclerosis. Mayo Clinic Proceedings 1997;72:765-80.
8. Kurtzke JF. Rating Neurologic Impairment in Multiple Sclerosis: An Expanded Disability Status Scale. Neurology 1983;33:1444-52.
9. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: Results of an international survey. Neurology 1996;46:907-11.
10. Poser CM, Paty DW, Scheinberg L, McDonal WI, Davis FA, Ebers GC, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Annals of Neurology 1983;13:227-31.